← Back to headlines
Allogene stock rises on positive phase 2 data for B-cell lymphoma treatment
Allogene Therapeutics saw its stock jump following an analysis of phase 2 data for its B-cell lymphoma asset, cema-cel.
13 Apr, 14:37 — 13 Apr, 14:37
Sources
Showing 1 of 1 sources
